Metastatic renal cell cancer.
Targeted therapy is the treatment of choice in patients with metastatic renal cell cancer (mRCC) at most institutions although a combination of cytokine therapy and targeted therapy still is being investigated. Morphological size-based criteria (RECIST) has failed in monitoring the effect of targeted therapy in patients with mRCC, as successful therapy often does not result in a decrease in tumour size. Modifications of size-based criteria and criteria based on computed tomography (CT) contrast enhancement has been introduced. Different imaging modalities that rely on characteristics other than size such as dynamic contrast-enhanced (DCE) ultrasonography, DCE CT, DCE magnetic resonance imaging (MRI), diffusion-weighted MRI, positron emission tomography and texture analysis seem to contribute with prognostic information, even at baseline scans, and can predict tumour response early after initiating therapy. No new standard for the imaging follow-up of targeted therapy in mRCC has been established.
Department of Radiology, Aarhus University Hospital, Denmark.
Finn
F
Rasmussen
D002292:Carcinoma, Renal Cell / Q000175:diagnosis* / Q000401:mortality / Q000556:secondary; D003287:Contrast Media; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D008279:Magnetic Resonance Imaging; D049268:Positron-Emission Tomography; D014057:Tomography, X-Ray Computed
D003287:Contrast Media